Incyte Q4 GAAP EPS $0.13; Non-GAAP EPS $0.62
AstraZeneca Says Forxiga Approved In EU For Treatment Of Symptomatic Chronic Heart Failure
Roche Reports Positive Results From Phase 3 COMMODORE 2 Study, Evaluating Efficacy And Safety Of Crovalimab
Viridian Therapeutics Appoints Scott Myers As President And CEO
LAVA Therapeutics Appoints Charles Morris As Chief Medical Officer